PCM
CYTK icon

Polymer Capital Management’s Cytokinetics CYTK Stock Holding History

Polymer Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,014
Closed -$509K – 870
2025
Q4 		$509K Buy
+8,014
New +$499K 0.05% 460

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Polymer Capital Management's CYTK Position: Q1 2026 in Review

Polymer Capital Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 8,014 shares — an estimated $509K sold.

Polymer Capital Management first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $509K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Polymer Capital Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 8,014 Cytokinetics shares in Q1 2026, an estimated $509K.
  • Polymer Capital Management first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
  • Polymer Capital Management's Cytokinetics position peaked at $509K in Q4 2025.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.